Skip to content
Calculator
Evidence: LowPeptide Clinical Trials Pipeline & In-Development

HM15275

also known as: HM-15275

Hanmi's triple-agonist GLP-1/GIP/glucagon candidate, mechanistically analogous to retatrutide — Phase 2 in obesity with a monthly-dosing ambition enabled by Hanmi's LAPSCOVERY platform.

A triple GLP-1 / GIP / glucagon receptor agonist peptide in Phase 2 by Hanmi Pharmaceutical — mechanistically the same class as retatrutide (Lilly) — distinguished by Hanmi's LAPSCOVERY Fc-conjugation platform, which is designed to support less-than-weekly dosing intervals (potentially monthly).

Mechanism of action

Balanced triple agonism at GLP-1, GIP, and glucagon receptors — same pharmacological concept as retatrutide. Glucagon agonism adds an energy-expenditure component that drives greater weight loss than dual GLP-1/GIP approaches in preclinical work.

Primary uses

  • Obesity (Phase 2)

Typical dosing

weekly or less frequent (subcutaneous)

Phase 2 doses not publicly finalized.

Regulatory status

Not approved. Phase 2 in obesity.

Status as of this entry's last review, April 19, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.

What the studies show

HM15275 is an injectable candidate from Hanmi Pharmaceutical for obesity and type 2 diabetes. Its registered trials are one completed phase 1 and two phase 2 trials under way; no paper on it is in PubMed yet.

Registry · 2024

Phase 1

Single and multiple subcutaneous doses in 74 healthy adults and people with obesity, completed in May 2025.

NCT06481098 · ClinicalTrials.gov record

Registry · 2025

Phase 2 in obesity

HM15275 against placebo in 267 people with obesity or overweight without diabetes; active, not recruiting, with primary completion expected in January 2027.

NCT07205900 · ClinicalTrials.gov record

Registry · 2026

Phase 2 in type 2 diabetes

HM15275 against placebo in 180 people with type 2 diabetes, recruiting since May 2026.

NCT07527650 · ClinicalTrials.gov record

References

  1. [manufacturer] Hanmi Pharmaceutical pipeline page — HM15275 triple agonist.
  2. [clinicaltrials] ClinicalTrials.gov NCT06481098: "A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects." Hanmi Pharmaceutical Company Limited. Phase 1, completed, May 2024 to May 2025 (primary completion), 74 participants. Registry record read October 2, 2026.
  3. [clinicaltrials] ClinicalTrials.gov NCT07205900: "Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus" Hanmi Pharmaceutical Company Limited. Phase 2, active not recruiting, December 2025 to January 2027 (primary completion), 267 participants. Registry record read October 2, 2026.
  4. [clinicaltrials] ClinicalTrials.gov NCT07527650: "Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus" Hanmi Pharmaceutical Company Limited. Phase 2, recruiting, May 2026 to October 2027 (primary completion), 180 participants. Registry record read October 2, 2026.

Related peptides

Guides & tools

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.